DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the discontinuation of its Phase 3 ICoN-1 clinical trial evaluating ...
Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update. As a reminder, this call is being recorded on November 10, 2025, and will be available for ...
DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback